10-Q: Stereotaxis Reports Q3 2024 Results, Impacted by Acquisition and Market Factors

Stereotaxis' Q3 2024 results show a revenue increase but also a net loss, influenced by the acquisition of Access Point Technologies EP, Inc. and ongoing market challenges.

Summary

• Stereotaxis reported a revenue increase to $9.2 million for the three months ended September 30, 2024, compared to $7.8 million for the same period in 2023.
• The company's net loss for the quarter was $6.2 million, compared to a net loss of $5.4 million in the prior year.
• For the nine months ended September 30, 2024, revenue decreased to $20.6 million from $22.2 million in the same period of 2023.
• The net loss for the nine-month period was $16.5 million, compared to a net loss of $15.7 million in the prior year.
• The acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024, added $0.6 million in revenue and a net loss of $1.2 million to the quarter's results.
• The company's gross margin decreased to 45% for the quarter, down from 52% in the same period last year, primarily due to changes in product mix and acquisition related accounting.
• Operating expenses increased to $10.4 million for the quarter, up from $9.7 million in the prior year, driven by the remeasurement of contingent consideration related to the APT acquisition.
• The company's cash and cash equivalents totaled $10.7 million as of September 30, 2024, down from $19.8 million at the end of 2023.

Sentiment

Score: 4

Explanation: The document presents mixed results with revenue growth offset by increased losses and decreased margins. The acquisition of APT is a positive strategic move, but the integration risks and ongoing market challenges temper the overall outlook.

Positives

• Revenue increased by 18% in Q3 2024 compared to Q3 2023, driven by increased system sales volumes.
• The acquisition of APT is expected to provide in-house catheter development and manufacturing expertise.
• The company has strategic relationships with technology leaders and innovators in the global interventional market.
• The company has received regulatory clearances and approvals necessary to market the Genesis RMN System in the U.S. and Europe.

Negatives

• The company experienced a net loss of $6.2 million in Q3 2024, an increase from the $5.4 million loss in Q3 2023.
• Gross margin decreased to 45% in Q3 2024, down from 52% in Q3 2023.
• Cash and cash equivalents decreased to $10.7 million as of September 30, 2024, from $19.8 million at the end of 2023.
• The company's working capital decreased to $8.1 million as of September 30, 2024, from $20.0 million as of December 31, 2023.
• The company incurred a $672,000 expense due to the revaluation of contingent consideration related to the APT acquisition.

Risks

• The company is experiencing periodic worldwide supply chain disruptions, including shortages and inflationary pressures.
• Hospitals are facing staffing and cost pressures, which may cause delays or cancellations of purchase orders.
• Disruptions to the capital markets could negatively impact the company's ability to raise capital.
• The COVID-19 pandemic and any resurgences may negatively affect demand for the company's products.
• The company is still integrating the APT business and implementing safeguards to minimize negative impacts.
• The manufacturing process of catheters is complex and subject to supply chain disruptions.
• The company may require a higher level of overhead than currently anticipated due to the APT acquisition.

Future Outlook

The company anticipates periodic disruptions to its manufacturing operations, supply chains, procedure volumes, service activities, and capital system orders and placements due to ongoing pandemic-related issues. The company also expects to manage APT's ongoing business of manufacturing, commercializing, development and sales of APT's catheters and related products and services.

Management Comments

• The integration with APT provides in-house catheter development, manufacturing expertise and specialized knowledge that will further Stereotaxis innovation efforts.
• The company is still integrating the businesses and implementing safeguards to minimize any negative impacts on our financial position, results of operations and cash flows post-acquisition.

Industry Context

The company operates in the multi-billion-dollar medical device market for cardiac ablation, which is expected to experience substantial long-term growth. The acquisition of APT is a strategic move to expand the company's product offerings and capabilities in this market. The company's robotic magnetic navigation technology is designed to improve the precision, stability, reach, and safety of endovascular interventions.

Comparison to Industry Standards

• The company's gross margin of 45% for the quarter is lower than some established medical device companies, which often have gross margins above 60%.
• The company's net loss indicates that it is still in a growth phase and not yet profitable, which is common for companies in the medical device sector that are investing heavily in research and development.
• The company's cash position of $10.7 million is relatively low compared to larger, more established medical device companies, which may have hundreds of millions or billions in cash reserves.
• The company's reliance on strategic relationships with fluoroscopy system manufacturers and other providers is a common practice in the medical device industry, but it also introduces risks related to the continuity of these relationships.
• The company's focus on robotic magnetic navigation is a niche area within the broader medical device market, and its success depends on the adoption of this technology by hospitals and physicians.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased gross margin.
• Employees may be affected by the integration of APT and any associated organizational changes.
• Customers may experience disruptions due to supply chain issues and the integration of APT.
• Suppliers may be affected by the company's efforts to manage supply chain disruptions.

Next Steps

• The company will continue to integrate the APT business.
• The company will pursue regulatory approvals for the Stereotaxis MAGiC catheter.
• The company will continue to monitor and address supply chain disruptions and inflationary pressures.

Key Dates

Keywords

Robotic Magnetic Navigation, Cardiac Ablation, Electrophysiology, Genesis RMN System, Odyssey Solution, Interventional Devices, Catheters, Acquisition, Financial Results, Supply Chain, Healthcare, Medical Devices